Divis Laboratories Enters ₹3 Trillion Market Cap Club After 15% Post-Earnings Surge
Shares of active pharmaceutical ingredient (API) and contract development major Divi's Laboratories jumped to fresh all-time highs, propelling the pharmaceutical heavyweight into the elite ₹3 trillion market capitalisation club for the first time. The stock surged 15% across two trading sessions following the announcement of robust financial results for the quarter ended September 30, 2026 (Q2FY27).
Divi's Laboratories shares hit an intraday record of ₹11,818 on the BSE, advancing over 7% during Monday's session. This followed a 7.5% rise during the special Diwali Muhurat trading session. With this rally, the company extended its winning streak to 12 consecutive trading days, racking up gains of 32% over that timeframe and soaring 105% from its 52-week low of ₹5,648 recorded on April 2, 2026.
At its intraday valuation of approximately ₹3.09 trillion, Divi's Laboratories rose to the 30th position in overall market capitalisation rankings on Indian bourses, overtaking public sector giants such as Oil and Natural Gas Corporation (ONGC) and Bharat Electronics, as well as Bajaj Group heavyweights Bajaj Auto and Bajaj Finserv.
Operational Highlights in Q2FY27
The steep re-rating follows an earnings beat driven by strong execution across active pharmaceutical ingredients and custom synthesis businesses:
- Net Profit: Consolidated profit after tax jumped 64% year-on-year (YoY) to ₹1,127 crore, up from ₹689 crore in Q2FY26.
- Revenue from Operations: Topline revenue increased 35% YoY to ₹3,676 crore compared to ₹2,715 crore in the year-ago period.
- Operating Margins: Earnings before interest, taxes, depreciation, and amortisation (EBITDA) surged 76% YoY to ₹1,566 crore, with EBITDA margin expanding by 990 basis points to 42.6% from 32.7%.
Segmentally, Custom Synthesis (CS) served as the primary growth engine, expanding 44% YoY to ₹2,200 crore. The generics segment grew 4.3% YoY to ₹1,050 crore, supported by volume gains, while nutraceuticals revenue advanced 13% YoY to ₹273 crore.
Brokerages Bullish on CDMO and Peptides Pipeline
Institutional analysts attributed the earnings outperformance to commercial scale-ups, validation batches, and capacity expansions in advanced therapy segments.
Brokerage firm Jefferies maintained a 'Buy' rating on the stock with a revised target price of ₹12,550, noting that EBITDA margins touched their highest levels since the pandemic era and that several contract development and manufacturing (CDMO) programs are nearing commercial production.
Goldman Sachs reiterated its positive stance, citing that revenue and operating margins substantially outperformed street consensus, led by momentum in custom synthesis. Meanwhile, JPMorgan highlighted the company's aggressive capacity buildup in multi-tonne solid-phase peptide synthesis (SPPS) reactors, positioning Divi's to capture burgeoning global demand in peptide and GLP-1 manufacturing.
For Indian equity investors, Divi's Laboratories' entry into the ₹3 trillion market valuation tier reflects strong institutional rotation toward research-backed healthcare and export-driven manufacturing companies with visible long-term order books.
